Study on the Therapeutic Effect of Biphenotypic Primary Hepatocellular Carcinoma
Objective To explore the therapeutic effect of biphenotypic primary hepatocellular carcinoma.Methods A total of 1 151 patients with primary hepatocellular carcinoma diagnosed and treated in Mengchao Hepatobiliary Hospital of Fujian Medical University from March 2020 to March 2022 were selected as the study objects.According to the pathological classification,they were divided into the control group(non-biphenotypic primary hepatocellular carcinoma,575 cases)and the study group(biphenotypic primary hepatocellular carcinoma,576 cases).Both groups were treated with laparoscopic hepatectomy or open surgery.The survival and serum biochemical indexes of the two groups were compared.Results The survival time of the study group was(2.14±0.23)years,shorter than that of the control group(3.96±1.02)years.The 1,3 and 5-year survival rates of the study group were lower than those of the control group(P<0.05).Alpha-fetoprotein(AFP),total bilirubin(TBIL)and albumin(ALB)of the study group were higher than those of the control group,while glutamyltransferase(GGT),alkaline phosphatase(ALP)and platelet(PLT)of the study group were lower than those of the control group,with statistical significance(P<0.05).Conclusion Compared with non-biphenotypic hepatocellular carcinoma,biphenotypic hepatocellular carcinoma has higher malignant degree,shorter survival time,and worse prognosis.
万方数据
维普
